Berkeley Heights, NJ, October 28, 2003
The conference call can be accessed as follows:
U.S./Canada: Dial (877) 634-8606, reference Q3 Earnings.
International: Dial (706) 679-3140, reference Q3 Earnings.
A replay will be available two hours after the completion of the
conference call and archived through Sunday, November 30, 2003,
accessible as follows:
U.S./Canada: Dial (800) 642-1687, enter 3679141 for conference ID.
International: Dial (706) 645-9291, enter 3679141 for conference
ID.
The webcast will be available in the Investor Relations section
of the Company's website at:
http://www.genta.com/genta/InvestorRelation/events.html
and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA and DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company's lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical testing. The
leading drug in Genta's small molecule program is Ganite
TM
(gallium nitrate injection), which the Company is exclusively
marketing in the U.S. for treatment of patients with cancer-related
hypercalcemia that is resistant to hydration. For more information
about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the conference call to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements
and forecasts involve risks and uncertainties because they relate
to events and depend on circumstances that will occur in the
future. There are a number of factors that could cause actual
results and developments to differ materially. For a discussion
of those risks and uncertainties, please see the Company's Annual
Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
